Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.74 |
| ▸ | MAOA | P21397 | 5/20 | 0.74 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.73 |
| ▸ | BCHE | P06276 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.66 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.65 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | CTSB | P07858 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3041716 | 1.00 | MAOB (0.74) | MAOBMAOACYP1B1BCHEMAPT | |
| SCHEMBL3041719 | 1.00 | MAOB (0.74) | MAOBMAOACYP1B1BCHEMAPT | |
| SCHEMBL3052868 | 1.00 | MAOB (0.74) | MAOBMAOACYP1B1BCHEMAPT | |
| SCHEMBL6733848 | 0.92 | MAOB (0.85) | MAOBMAOACYP1B1BCHEMAPT | |
| SCHEMBL6733854 | 0.92 | MAOB (0.85) | MAOBMAOACYP1B1BCHEMAPT | |
| SCHEMBL9136943 | 0.86 | MAOB (0.80) | MAOBMAOACYP1B1BCHEMAPT | |
| SCHEMBL8977012 | 0.86 | MAOB (0.76) | MAOBMAOACYP1B1BCHEMAPT | |
| SCHEMBL8977005 | 0.86 | MAOB (0.76) | MAOBMAOACYP1B1BCHEMAPT | |
| SCHEMBL9136940 | 0.86 | MAOB (0.80) | MAOBMAOACYP1B1BCHEMAPT | |
| SCHEMBL8965786 | 0.86 | MAOB (0.76) | MAOBMAOACYP1B1BCHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113845524-B | Spiropyrrolindolone compound and preparation method and application thereof | 四川农业大学 | 2023-11-07 | — | — | CN | disclosed |
| CN-113845524-A | Spiropyrrole indolone compound and preparation method and application thereof | 四川农业大学 | 2021-12-28 | — | — | CN | disclosed |
| US-20100278733-A1 | COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE | NAGASAKI UNIVERSITY (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2030635-A1 | COMPOSITION FOR DIAGNOSING AMYLOID-RELATED DISEASE | Nagasaki University (JP) | 2009-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278733-A1 | COMPOSITION FOR DIAGNOSIS OF AMYLOID-RELATED DISEASE | APP, FABP7, APBA1 | MAOB 1093/4885MAOA 1220/4885CYP1B1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.